Evidence map›Paper›PMID 29497791›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2018

Nonmetastatic pancreatic cancer : Improved survival with chemoradiotherapy > 40 Gy after systemic treatment.

Sebastian Bachmayer, Gerd Fastner, Andrea Vaszi, Wolfgang Iglseder, Peter Kopp, Josef Holzinger, Adam Dinnewitzer, Gabriel Rinnerthaler, Simon Peter Gampenrieder, Klaus Emmanuel and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sebastian BachmayerDepartment of Radiotherapy and Radio-oncology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
Gerd FastnerDepartment of Radiotherapy and Radio-oncology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
Andrea VasziDepartment of Radiotherapy and Radio-oncology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
Wolfgang IglsederDepartment of Radiotherapy and Radio-oncology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
Peter KoppDepartment of Radiotherapy and Radio-oncology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
Josef HolzingerUniversity Clinic of Surgery, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
Adam DinnewitzerUniversity Clinic of Surgery, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
Gabriel RinnerthalerIIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
Simon Peter GampenriederIIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
Klaus EmmanuelUniversity Clinic of Surgery, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
Richard GreilIIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
Felix SedlmayerDepartment of Radiotherapy and Radio-oncology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
Franz ZehentmayrDepartment of Radiotherapy and Radio-oncology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria. f.zehentmayr@salk.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe role of radiotherapy (RT) for nonmetastatic pancreatic cancer is still a matter of debate since randomized control trials have shown inconsistent results. The current retrospective single-institution study includes both resected and unresected patients with nonmetastasized pancreatic cancer. The aim is to analyze overall survival (OS) after irradiation combined with induction chemotherapy. PATIENTS AND

methodsOf the 73 patients with nonmetastatic pancreatic cancer eligible for the present analysis, 42 (58%) patients had adjuvant chemoradiotherapy (CRT), while 31 (42%) received CRT as primary treatment. In all, 65 (89%) had chemotherapy at any time before, during, or after RT, and 39 (53%) received concomitant CRT. The median total dose was 50 Gy (range 12-77 Gy), while 61 (84%) patients received >40 Gy.

resultsWith a median follow-up of 22 months (range 1.2-179.8 months), 14 (19%) are still alive and 59 (81%) of the patients have died, whereby 51 (70%) were cancer-related deaths. Median OS and the 2‑year survival rate were 22.9 months (1.2-179.8 months) and 44%, respectively. In addition, 61 (84%) patients treated with >40 Gy had a survival advantage (median OS 23.7 vs. 17.3 months, p = 0.026), as had patients with 4 months minimum of systemic treatment (median OS 27.5 vs. 14.3 months, p = 0.0004).

conclusionCRT with total doses >40 Gy after induction chemotherapy leads to improved OS in patients with nonmetastatic pancreatic cancer.

Indexed as

Induction ChemotherapyRadiotherapy DosageAgedAged, 80 and overChemoradiotherapyChemoradiotherapy, AdjuvantCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleMiddle AgedPancreatic NeoplasmsSurvival RateAdjuvant chemotherapyOverall survivalPancreatic cancerRetrospective analysisSurgery

Identifiers

PMID29497791
PMCPMC6008353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.